{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL7K9-cKDA","lastupdate":"2022-12-02T00:00:00.000Z","update_date":"2022-12-02T00:00:00.000Z","lastModified":"Dec 19, 2024","active":1,"confidence_score":89,"confidence_score_reason":"funding rounds, markets, not claimed","urlname":"savicell-diagnostics","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$dX5xRIT3WjZ6nnkKoBHgT1l17rTNEmTsdlvuVYCRpw95JzkGHd8xZa","name":"Savicell Diagnostics","oneliner":"Blood Test for Early Cancer Detection","registrar":"514764091","website":"https://www.savicell.com","careerspage":"http://www.savicell.com/careers.html","founded_month":4,"founded_year":2012,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/12622819","instagram":""},"social":["https://www.linkedin.com/company/12622819"],"flattenedsociallinks":"https://www.linkedin.com/company/12622819","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":8,"patent":1,"raised":0,"stage":"Pre-Funding","public_stage":"Pre-Funding","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, with a focus on cancer. The Well-Shield technology is designed to detect and interpret differential metabolic responses that can indicate disease intrusion and cell malformation, including cancer.\n\nThe company aspires to improve adherence to routine medical screenings through the use of patient-friendly blood tests. Savicell Diagnostics is a majority-owned subsidiary of Savicell Corporation, a Nevada-based corporation.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"03f50e65-c01c-4c79-95b1-409a682eb22e","city":"Haifa","type":null,"address":"Matam, Haifa, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"North District","news":[{"id":"R1XMzusHw8nyzDxtSMqvV19W8PUNWv23kPBumIyKDIFA8XPM4P5cpX","date":"Jun 22, 2023","link":"https://13tv.co.il/item/news/domestic/health/x2jyl-903580990/","source":"13tv.co.il","visible":1,"analysis":{"tags":"Medical Innovation","company":"Not mentioned","layoffs":"Not mentioned","summary":"A new, simple, and affordable blood test developed in Israel can detect lung cancer within a few hours, potentially saving lives. This test, which has not yet been officially approved, successfully identified the disease in one of the trial participants, saving their life. The test works by asking white blood cells if they have encountered cancer. This breakthrough represents a significant advancement in medical technology and cancer detection, particularly for lung cancer, which is notoriously difficult to diagnose early.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Blood Test","Lung Cancer","Early Detection","Medical Technology","Israel"],"date_of_event":"22.06.2023","valuation_amount":"Not mentioned","impact_on_company":"Not applicable","investment_amount":"Not mentioned","structured_issues":[],"acquisition_amount":"Not mentioned","entityGrowthIconPath":"none;"},"sentiment":"Not applicable","analysisId":"RpqpHkRwnH3JTnp709L6tL9dm1hcOTmomNq7uI6BNjuH8PcFFsUYQS","news_summary":"\"הצלחנו להציל חיים\": כך פועלת הבדיקה שמזהה סרטן בתוך 5 שעות | חדשות 13","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"30d34a28-d985-47db-a350-e7c427fa4254","date":"Sep 9, 2021","link":"https://www.bioworld.com/articles/511254-savicell-touts-high-accuracy-results-for-its-liquid-biopsy-platform?v=preview","source":"www.bioworld.com","visible":1,"analysis":{"tags":"biopharma, medtech","company":"Savicell Diagnostics Ltd.","layoffs":null,"summary":"Savicell Diagnostics Ltd. has reported high accuracy results for its liquid biopsy platform Immunobiopsy in identifying lung cancer. The platform achieved 97% sensitivity and 97% specificity in a study with 245 participants. This news is growth-positive for the company.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["liquid biopsy","Immunobiopsy","lung cancer","accuracy","study"],"date_of_event":"September 9, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"J4btoXbLtzUN8RwA60XduLtCYZv6fJKWjtT6rLi9OfSkH9NcuNqDzi","news_summary":"Savicell touts high accuracy results for its liquid biopsy platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"U9ih53JsdrAghQ6n0CtCHuuKybrLojdMsus7up52cPd6Yjy4cYCrZY","date":"Aug 24, 2021","link":"https://www.manufacturingchemist.com/news/article_page/Orgenesis_to_collaborate_with_Savicell_on_ImmunoBiopsy_platform/178769","source":"www.manufacturingchemist.com","visible":1,"analysis":{"tags":"collaboration, diagnostic kits, quality control, monitoring, cell and gene therapies","company":"Orgenesis","layoffs":null,"summary":"Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to develop and validate diagnostic kits for quality control and monitoring purposes in the manufacturing and processing of its cell and gene therapies. Orgenesis will have exclusive rights to use and sell the kits, which will be used within its point-of-care platform. The collaboration aims to enhance the potency of therapies and develop companion diagnostics for targeted patient treatment. The initial focus will be on lung cancer treatments, with plans to expand to other cancer types and diseases. The collaboration will leverage Savicells ImmunoBiopsy platform. The CEO of Orgenesis sees promise in early cancer detection using the technology.","partners":"Savicell Diagnostics","customers":null,"investors":null,"confidence":9,"key_topics":["Collaboration","Diagnostic kits","Quality control","Monitoring","Cell and gene therapies"],"date_of_event":"24-Aug-2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DbvYxATmummdP5WcBrH4ebLjgDmjNYCNbJihhEtGvffl6U7LJrVX3b","news_summary":"Orgenesis to collaborate with Savicell on ImmunoBiopsy platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"38da7c37-89f1-4484-9fef-5a023fd8e8d6","date":"Aug 29, 2019","link":"https://www.timesofisrael.com/startup-says-its-blood-test-can-detect-early-stage-lung-cancer/?utm_source=Startup+Daily&utm_campaign=startup-daily-2019-08-29&utm_medium=email","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":"lung cancer detection","company":"Savicell Diagnostics","layoffs":null,"summary":"Israeli startup Savicell Diagnostics has developed a blood test for the early detection of lung cancer. The companys ImmunoBiopsy test analyzes the metabolic profile of the immune system to identify signs of the disease. The test has shown promising results in distinguishing between various ailments, including cancers, autoimmune diseases, and infectious diseases. Savicell has already conducted testing at leading Israeli hospitals and has a more advanced product for lung cancer detection. While the technology is promising, there are still limitations in terms of sensitivity and accuracy. Other companies in the field of liquid biopsy and early detection of lung cancer include Nucleix Ltd., which uses DNA sequencing for diagnosis.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["lung cancer detection","blood tests","liquid biopsy","immune system","metabolic profile"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"umRNjznrd1zIKk4a3tlbOk9torOKj49TRargxuOublxwXkngDrGEI5","news_summary":"Startup says its blood test can detect early-stage lung cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f5207dc8-971c-4458-b1f0-637de1c2f325","date":"Jul 29, 2019","link":"https://www.israel21c.org/revolutionary-blood-test-will-detect-stage-1-lung-cancer/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"diagnostic test","company":"Savicell","layoffs":null,"summary":"Israeli startup Savicell is developing a new blood test to diagnose lung cancer. The company uses immunometabolism to measure the metabolic state of immune cells in the blood, allowing for early detection of lung cancer. Savicells diagnostic kit can identify lung cancer with 91 percent sensitivity. The company has conducted research with 200 patients in Israel and has raised $9 million in funding. Savicell is focused on lung cancer but plans to expand its approach to other types of cancer and autoimmune conditions.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["lung cancer","liquid biopsy","immunometabolism","diagnostic kit","blood test"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hsE3BXLgO5VJiLndiCcyjIHTWZo9gthkKHBj9n41ReM4adFgjCGKmc","news_summary":"Revolutionary blood test will detect stage 1 lung cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5e7c5b9b-765d-44fe-ad97-3f32c1379b12","date":"Jun 25, 2019","link":"https://en.globes.co.il/en/article-savicell-develops-cancer-blood-test-1001290914","source":"en.globes.co.il","visible":1,"analysis":{"tags":"biotechnology, cancer diagnosis, blood test, immuno-metabolism","company":"Savicell","layoffs":null,"summary":"Israeli company Savicell is developing a blood test for early diagnosis of cancer based on immuno-metabolism. The test measures the changes in energy utilization within immune system cells when encountering certain diseases. Savicells product has not yet received FDA approval, but a clinical trial in Israel showed promising results with a sensitivity of 91% and specificity of 80%. The company aims to provide earlier diagnosis for lung cancer, which has a higher survival rate when detected at Stage I. Savicell differentiates itself from other companies in the field by focusing on diagnosis rather than therapeutic processes. The companys test is more sensitive and can detect cancer at earlier stages. Savicells competitors mainly focus on sequencing technologies of genetic material secreted by cancer cells.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["cancer diagnosis","immuno-metabolism","blood test","liquid biopsy","early diagnosis"],"date_of_event":"June 25, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vOwPcONGUwjX1qUdWgu1BAGMfF2Ge6nShBvjhEMTmzsVgBQna0ixrS","news_summary":"A blood test that detects cancer early","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f29c0536-ea7c-43f1-9d38-e4a61043b7fc","date":"Oct 10, 2018","link":"https://globenewswire.com/news-release/2018/10/10/1619610/0/en/Online-Disruptive-Technologies-Announces-Publication-of-Results-in-Cancer-Journal.html","source":"globenewswire.com","visible":1,"analysis":{"tags":"lung cancer clinical study, liquid ImmunoBiopsy, early detection of disease, cancer liquid biopsy market","company":"Online Disruptive Technologies, Inc.","layoffs":null,"summary":"Online Disruptive Technologies, Inc. announces that its lung cancer clinical study results were published in the scientific journal Cancer Immunology and Immunotherapy. The study validates the promise of Savicells Liquid ImmunoBiopsy platform for the early detection of lung cancer. The platform achieved 91% sensitivity and 80% specificity in diagnosing lung cancer, even in Stage 1. Savicells Well-Shield platform is designed for the early detection of diseases. The companys initial focus is on the cancer liquid biopsy market.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["lung cancer clinical study","Savicell Diagnostics","Liquid ImmunoBiopsy","early detection of disease","cancer liquid biopsy market"],"date_of_event":"October 10, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Lgm39Eih4lSdIA4sIPxxaAc1Y1bkuJjaaCwQxrEseMKbBMHW6Xmafg","news_summary":"Online Disruptive Technologies Announces Publication of Results in Cancer Journal","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"31d68ca3-fe4d-49cc-bca3-2aa5036635fa","date":"Sep 4, 2018","link":"https://www.globenewswire.com/news-release/2018/09/05/1565330/0/en/Online-Disruptive-Technologies-Appoints-Executive-VP-of-Research-Development.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"appointment","company":"Online Disruptive Technologies, Inc.","layoffs":null,"summary":"Online Disruptive Technologies, Inc. has appointed Dr. Shafrira Shai as Executive Vice-President of Research & Development at its subsidiary, Savicell Diagnostic Ltd. Dr. Shai brings 20 years of management experience in medical diagnostics, medical devices, and pharmaceuticals. Savicell has a liquid ImmunoBiopsy platform for early disease detection, with a focus on the cancer liquid biopsy market. The appointment of Dr. Shai is expected to have a positive impact on the companys growth.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["appointment","research and development","medical diagnostics","liquid biopsy","cancer"],"date_of_event":"September 4, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jmMENYzlczZeHTUZQLvg4SVKIMNjnE7UnLPvqmSNqwRXL7UTpd2rW0","news_summary":"Online Disruptive Technologies Appoints Executive VP of Research & Development","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3ebfd182-c07e-4b51-9fb4-2817c4aa34c1","date":"Oct 8, 2013","link":"https://www.fiercebiotech.com/medical-devices/exact-sciences-denies-talks-underway-to-invest-israeli-cancer-dx-startup","source":"www.fiercebiotech.com","visible":1,"analysis":{"tags":"Legal","company":"Questex LLC","layoffs":"N/A","summary":"The article does not provide any specific information about Questex LLC.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":10,"key_topics":[],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"N/A","investment_amount":"N/A","structured_issues":[],"acquisition_amount":"N/A","entityGrowthIconPath":"none;"},"sentiment":"N/A","analysisId":"U2XRJDxLV7nDJ82Vu9e2nAM4d0xjY1MbTzt0vg6AnbDbsvwpQs97PL","news_summary":"Exact Sciences denies talks underway to invest in Israeli cancer Dx startup","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":9,"events":null,"techcommunityinvolvement":null,"mediagallery":[{"id":"7YZkxqbU8NhL9oXWqhYyZRVsqowV4TA5daxyHKRSmZ9Ai5eEeSC4XM","timestamp":"2024-12-19 14:09:23.000000","resources_type":2,"resources_title":"Powerful example of the platform’s potential, from Savicell’s clinical trials for lung cancer.","resources_file_name":"iLWRZnmYx1Y?si=TeOtIYY4ts4_3EHl","alt":"Powerful example of the platform’s potential, from Savicell’s clinical trials for lung cancer. logo","imageurl":"https://img.youtube.com/vi/iLWRZnmYx1Y?si=TeOtIYY4ts4_3EHl/0.jpg","url":"http://youtu.be/iLWRZnmYx1Y?si=TeOtIYY4ts4_3EHl"}],"tags":["diagnostics","medical-technologies","blood-test","biotechnology","cancer","early-detection","clinical-data","oncology","clinics","hospitals","academia","laboratories","healthcare-providers","minimally-invasive","pulmonary"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA"],"technologysuccessstory":[{"date":"2012-04-01","name":"Early detection of diseases by measuring metabolic activity in the immune system","tags":["cancer-diagnostics","immunology","early-detection"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/ramot_tto_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda7","university_logo":"/image_cloud/ramot_institution_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["Well-Shield"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":0,"fundingstage":"Pre-Funding","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":null,"totalpublicrounds":0,"totalpublicfunding":0},"team":[{"name":"Giora Davidovits","email":"giorad@savicell.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGyoKwIDA","bounced":false,"claimed":0,"founder":0,"urlname":"giora-davidovits","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAsdudyAoM","position":"CEO & President","last_name":"Davidovits","claimtoken":"lSUubftAnwnHdppZ6xoPqL2sA3vPzgcdoXyJ8gymQHmvuQa8XS93J4","first_name":"Giora","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/giora-davidovits-b2530/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-02 18:55:41.000000","initials":"GD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eyal Davidovits","email":"eyald@savicell.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLq07vMJDA","bounced":false,"claimed":1,"founder":0,"urlname":"eyal-davidovits","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg2tWUpgkM","position":"COO","last_name":"Davidovits","claimtoken":"qoYe3BU98ib5bo7BqFU71sKWfOOfoxnADgcHS94SsWgpUOqv49Gmtv","first_name":"Eyal","picturekey":null,"claimeddate":"2024-12-19","linkedinurl":"https://www.linkedin.com/in/eyaldavidovits/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-02 18:56:16.000000","initials":"ED","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Shafrira  Shai","email":"shafriras@savicell.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4MzH6JoKDA","bounced":true,"claimed":0,"founder":0,"urlname":"shafrira-shai","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg7MK0tgkM","position":"VP R&D","last_name":"Shai","claimtoken":"QGLlG3WtP8vX2PrOZlJdaKs4A4GPM7CTbqrf1MosdUKAESyEeb30hr","first_name":"Shafrira ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/shafi-shay-38a94b199/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-02 18:56:14.000000","initials":"SS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Fernando Patolsky","email":"fernandop@savicell.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Kzyls4LDA","bounced":true,"claimed":0,"founder":1,"urlname":"fernando-patolsky-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgrKiHpAgM","position":"Principal Investigator and Inventor","last_name":"Patolsky","claimtoken":"IS5IrVaVXON6wYqCl0suM1MXrT4fA8IjPu5ouGn9CJCPoftwDpzqRT","first_name":"Fernando","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-02 18:56:02.000000","initials":"FP","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-02-14T00:00:00.000Z","crunchbaseid":"savicell-diagnostics","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Rebecca Mack","creator_email":"rebeccamack26@gmail.com","createdate":"2014-07-08T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"4/2012","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Savicell Diagnostics","logourl":"https://storage.googleapis.com/clean-finder-353810/$dX5xRIT3WjZ6nnkKoBHgT1l17rTNEmTsdlvuVYCRpw95JzkGHd8xZa","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$dX5xRIT3WjZ6nnkKoBHgT1l17rTNEmTsdlvuVYCRpw95JzkGHd8xZa","seoabout":"Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, with a focus on cancer. The Well-Shield t...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Test Diagnostics & Screening","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Test Diagnostics & Screening#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Test Diagnostics & Screening#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Test Diagnostics & Screening","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Test Diagnostics & Screening"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Test Diagnostics & Screening","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Test Diagnostics & Screening"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}